Angiotech to participate in UBS Global Life Sciences ...(Such forward-looking statements involve ...)

Date:9/19/2007

Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements.

Many such risks, uncertainties and other factors are taken into account as part of our assumptions underlying these forward-looking statements and include, among others, the following: general economic and business conditions, both nationally and in the regions in which we operate; market demand; technological changes that could impact our existing products or our ability to develop and commercialize future products; competition; existing governmental regulations and changes in, or the failure to comply with, governmental regulations; adverse results or unexpected delays in drug discovery and clinical development processes; decisions, and the timing of decisions, made by health regulatory agencies regarding approval of our technology and products; the requirement for substantial funding to conduct research and development and to expand commercialization activities or consummate acquisitions; and any other factors that may affect performance. In addition, our business is subject to certain operating risks that may cause the actual results expressed or implied by the forward-looking statements in this report to differ materially from our actual results. These operating risks include: our ability to attract and retain qualified personnel; our ability to successfully complete preclinical and clinical development of our products; changes in business strategy or development plans; our failure to obtain patent protection for discoveries; loss of patent protection resulting from third party challenges to our patents; commercialization limitations imposed by patents owned or controlled by third parties; our ability to obtain rights to technology from licensors; liability for patent claim
'/>"/>

SOURCE Angiotech Pharmaceuticals, Inc. Copyright©2007 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3
Related biology technology :

1. Bruker Participates in Dutch Funded Super Microscope Project
2. World Class Life Science and Pharmaceutical Companies Leverage DoveBid s Global Reach for Asset Management and Disposition
3. The state of global biotech: An Ernst & Young perspective
4. Doyle announces new energy, global warming policies
5. Lucigen Corp. enters global licensing agreement
6. Global information firm reaches diverse markets
7. Work-life imbalance - A global problem getting worse
8. Leading global Big Pharma companies of 2005
9. Learning to swim in the global talent pool
10. Federal and global guidelines on stem cell research offer a level playing field
11. Midwest life-science company Perrigo globalizes under the radar